Table: Jcr Pharmaceuticals -Q1 group results
May 13 (Reuters)-
Jcr Pharmaceuticals Co., Ltd.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Jun 30, 2025 Jun 30, 2024 Mar 31, 2026
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 8.57 8.15 37.80
(+5.2 pct) (-24.6 pct) (+14.3 pct)
Operating loss 606 mln loss 296 mln 2.60
Recurring loss 749 mln loss 257 mln 2.40
Net loss 546 mln 201 mln 3.00
(-87.5 pct)
EPS loss 4.48 yen 1.61 yen 24.22 yen
EPS Diluted 1.61 yen
Ann Div 20.00 yen 20.00 yen
-Q2 div 10.00 yen 10.00 yen
-Q4 div 10.00 yen 10.00 yen
NOTE - Jcr Pharmaceuticals Co., Ltd..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4552.T
Recent news on JCR Pharmaceuticals
See all newsBrief: JCR Pharmaceuticals Receives Marketing Authorization In Kuwait For Izcargo
Italfarmaco And Jcr Pharmaceuticals Enter Into Exclusive License Agreement For Jr-141 In United States, Europe, And Latin America
Brief: Jcr Pharmaceuticals Receives Orphan Drug Designation For Givinostat In Japan
Brief: Medipal & JCR Dose First Patient In Global Phase I/II Trial OF JR-446 For Mucopolysaccharidosis Type IIIB
Table: Jcr Pharmaceuticals -Q1 group results